Select a Region North America

Insights

Insights From Our Experts

Articles

Linking Channel Distribution & 3PL to Non-Traditional Commercialization Touchpoints

To be competitive, maximize products and deliver exceptional customer service, trade and channel strategies must go beyond logistics. This presentation outlines how manufacturers need to connect the dots between customer type, whether they are specialty distributors,…

Balancing the Portfolio: How Extending Mature Brands’ Success Can Replenish Costs Invested In Launching New Products

The traditional mindset toward established brands in the pharmaceutical industry has largely been to let focus fade from them and shift entirely to developing and launching new products. With emphasis placed almost exclusively on new product…

Asset Optimization: Breathe New Life Into Mature Brands with EVERSANA REIGNITE™

Maximizing revenue potential throughout products’ entire lifecycles before they reach loss of exclusivity (LOE) is the most impactful return on investment manufacturers can make for their established brands. While many companies figuratively put their mature brands…

Maximizing Product Launch Success: The Importance of Conducting Comprehensive Business Simulation Exercises

Product launch preparedness is a vital aspect of bringing new products to market, particularly in the pharmaceutical industry where patients’ health and well-being can be impacted, in addition to the brand’s success and overall reputation. As…

Forecasting in the Age of Value-Based Agreements

The pharmaceutical industry faces a host of increasingly complex challenges and critical decisions when attempting to manage and predict their products’ plausible revenue patterns. The mishandling of revenue forecasting and evaluation can result in substantial financial…

Innovative Approaches to 340B Claims Data Identification

EVERSANA’s Chris Lagoerio, Vice President, Revenue Management participated in a panel session, “Innovative Approaches to 340B Claims Data Identification,” at the Medicaid & Government Pricing Congress alongside fellow industry leaders Andrew Brownlee, Associate Director, Berkeley Research…

Key Considerations When Operationalizing Revenue Management

Pharmaceutical manufacturers commonly invest a considerable amount of time, money and additional resources into revenue management. Most would likely say they desire to invest even more because of the significant impact it has on their products’…

Digital Guide to Commercializing Complex Therapeutics

Pharmaceutical manufacturers specializing in Rare Disease, Oncology, Personalized Cancer Immunotherapy, and Cell and Gene therapies encounter a range of complex challenges, including advancements in medicine and technology, changing patient and provider needs, market access, regulatory pathways,…

Key stakeholders in pricing strategies
Informing Optimal Pricing Strategies with a Comprehensive Modeling Approach

Strategically pricing new therapies has always been vitally important for pharmaceutical manufacturers. After the 2022 passing of the historic legislative package, known as the Inflation Reduction Act (IRA), strategic pricing strategies have become especially pivotal. The…

The State of National Healthcare Policy and Pricing Webinar 2023

2023 is shaping up to be an interesting year for Pharma/Biotech companies and their commercial and government pricing strategies and contracts. There are multiple policies and rules being discussed, already proposed, under review, in litigation, and…